论文部分内容阅读
已知大剂量静脉注射用免疫球蛋白(HDIVIG)对感染1型人类免疫缺陷症病毒(HIV-1)的儿童具有一定的治疗效果,但对成人患者疗效的研究甚少,为此,作者对AIDS相关复征(ARC)和Walter-Reed5(WR5)成人患者进行了一项随机分层双盲研究,以进一步了解IVIG对成人患者临床表现以及免疫学参数的影响。30例患者(男28例,女2例)中,具有ARC者8例,具有WR5者12例,两者都有者10例。按T4细胞计数(≥或<300/μl)进行分组。治疗组15例,按0.4g/kg体重注射IVIG;
High-dose intravenous immunoglobulin (HDIVIG) is known to have a therapeutic effect on children infected with human immunodeficiency virus type 1 (HIV-1), but little is known about the efficacy of treatment in adult patients. To this end, A stratified, randomized, double-blind study was conducted in adult patients with AIDS-related complex (ARC) and Walter-Reed5 (WR5) to further understand the effects of IVIG on clinical manifestations and immunological parameters in adult patients. Of the 30 patients (28 males and 2 females), 8 had ARC, 12 had WR5, and 10 had both. Group by T4 cell count (≥ or <300 / μl). The treatment group of 15 cases, according to 0.4g / kg body weight injection IVIG;